Ambient artificial intelligence (AI) scribe technology is entering clinical settings with the promise of reducing documentation burden. For health system leaders, these tools pose governance challenges rather than simple information technology upgrades. Early pilots show reductions of up to 30% in after-hours charting, but results vary with implementation quality. This article argues that Canada should classify AI scribes as Class II Software as a Medical Device and outlines governance questions for executives and boards. By treating ambient AI scribes as strategic leadership priorities – rather than technology deployments – healthcare leaders can balance efficiency with ethical stewardship and strengthen patient trust.

Introduction

Canadian healthcare leaders face mounting pressure to address clinician burnout, improve patient experience and manage scarce resources. Documentation remains a major driver of frustration, with many clinicians spending hours each evening completing notes. Ambient artificial intelligence (AI) “scribe” technology has emerged as a potential solution, automatically recording and drafting visit notes so clinicians can focus more on patients and less on keyboards.

For executives and boards, the promise is significant: reduced administrative burden, improved retention and better engagement between patients and providers. Yet, adoption raises complex questions of privacy, accountability and public trust. Unlike other digital tools, AI scribes operate directly in clinical encounters, placing them at the centre of patient–provider relationships.

Documentation burden affects the full spectrum of healthcare professionals. Nurses, nurse practitioners, physician assistants and allied health professionals spend substantial time on clinical documentation, each with distinct requirements tied to their regulatory bodies and scope of practice. Any governance framework for AI scribes must account for this interprofessional reality, ensuring that implementation, consent processes, privacy safeguards and accountability mechanisms are applied consistently across all clinical disciplines that document care.

The timing is critical. Health systems across Canada are experiencing workforce shortages, increased demand and pressure to accelerate digital transformation. In this environment, leaders are being asked to do more with less while safeguarding equity and trust. AI scribes offer one potential pathway to relieve front-line pressure, but only if implemented with careful governance.

This article examines what leaders need to know as ambient AI scribes move from pilots into broader use. It reviews evidence from early deployments, highlights ethical and legal considerations, explores why Canada should regulate these systems as Software as a Medical Device (SaMD) and sets out governance questions for boards and senior managers.

Clinical Outcomes and Implementation

Early deployments of ambient AI scribes produce promising but mixed results. Outcomes depend less on technology itself and more on how it is introduced, supported and governed.

Several US pilot studies provide encouraging signals. At Mass General Brigham, a six-week trial with more than 200 clinicians reported a 40% relative reduction in burnout symptoms (Peterson Health Technology Institute 2025). At MultiCare Health System, clinicians cited a 63% decrease in burnout and a 64% improvement in work-life balance (Peterson Health Technology Institute 2025). Peer-reviewed research shows measurable efficiency gains. A University of Pennsylvania study found a 20% reduction in time spent on documentation, a 9% increase in same-day note completion and a 30% decrease in after-hours “pajama time” (Duggan et al. 2025). These outcomes translate into improved retention, stronger engagement and more sustainable clinical workloads.

However, not all implementations succeed. In some cases, productivity gains were negligible (Peterson Health Technology Institute 2025). A controlled cohort study of one commercial product found a small increase in after-hours charting (Haberle et al. 2024). These findings underscore a critical lesson: AI scribes are not turnkey solutions. Success depends on workflow redesign, adequate training and continuous feedback loops.

Given this variability, healthcare organizations should adopt AI scribes through systematic piloting and evaluation before full deployment. A phased approach should embed AI scribes initially with specific clinical teams or professional groups to assess workflow integration and identify discipline-specific requirements. Organizations must implement robust change management processes, measure quantifiable impacts on documentation time and clinician satisfaction, identify and mitigate unintended consequences such as increased error correction burden or equity gaps in performance and establish clear success criteria before scaling. This evidence-based approach reduces organizational risk and ensures that broader deployment is justified by demonstrated benefits rather than vendor promises.

For leaders, AI scribes should be introduced as part of broader strategies for clinician well-being, supported by strong change management and realistic expectations. Pilots should measure efficiency, staff satisfaction, patient experience and unintended impacts on workload, with scaling occurring only when leaders have confidence that technology delivers net benefits in practice.

Ethical and Legal Considerations

Efficiency gains cannot come at the expense of accountability, trust or compliance. Four areas stand out.

Accountability for accuracy

Even when AI tools produce first drafts, clinicians remain legally and professionally responsible for final documentation. Studies highlight the risk of automation bias, where providers become over-reliant on AI output and fail to double-check critical details (Cohen et al. 2025). An incorrect medication dose transcribed as “5 mg” instead of “0.5 mg” illustrates how small errors escalate into serious safety risks. Leaders must reinforce policies, making clear that clinicians are authors of record, supported by training, audit processes and monitoring systems.

Patient trust and informed consent

AI scribes function as recording devices in exam rooms. Patients deserve transparency and genuine choice. Consent must be clear, revocable at any time and without impact on care. Ontario's Information and Privacy Commissioner emphasizes meaningful consent, visible indicators when recording is active and the ability to pause at patients' request (Minutti 2025).

Practical consent mechanisms should include visible signage in examination rooms indicating AI scribe capability, verbal confirmation at encounter starts, physical or digital buttons allowing patients to pause recording and documentation in clinical records indicating whether patients consented, declined or paused recording during sensitive portions of visits. Executives must embed these requirements into organizational policies and ensure that frontline staff have the tools to uphold them.

Privacy and compliance obligations

AI scribes collect and process protected health information, triggering obligations under Canadian privacy law. Healthcare organizations must hold vendors accountable for data security, access controls and secure storage. Business associate agreements and procurement contracts should explicitly address AI vendors and include audit rights. Leaders must be prepared to answer how data are stored, who has access and how breaches will be managed.

Mitigating automation bias and liability risk

Organizations face reputational and legal exposure if AI errors are not caught. Clinicians must treat AI-generated text as drafts, not facts. Leadership should support this through structured training, visible audit trails tracking both AI and clinician contributions and periodic review of documentation quality (Information and Privacy Commissioner of Ontario 2025).

Software as a Medical Device Classification in Canada

As ambient AI scribes become more prevalent, a critical question for healthcare executives and policy makers is how these tools should be regulated. Unlike electronic health records, AI scribes actively generate clinical documentation that becomes part of the medical record. This function directly influences patient care and therefore requires regulatory oversight.

International peers are already taking steps. The UK's National Health Service has mandated that ambient AI scribes be regulated at least as Class I medical devices, requiring registration with the Medicines and Healthcare products Regulatory Agency (NHS England 2025). If these tools extend beyond documentation into clinical decision support, higher classifications apply.

Under Health Canada's risk-based framework, AI scribes would likely qualify as Class II medical devices, representing moderate-risk products that inform clinical decisions but do not function autonomously (Health Canada 2025). This classification requires a medical device licence, manufacturer quality system certification (ISO 13485) and pre-market review, but stops short of the intensive clinical evidence requirements of Class III or IV devices. It appropriately balances the clinical impact of documentation errors against the lower direct patient-contact risk compared with implantable or life-sustaining devices.

SaMD classification would further require vendors to meet international standards for medical device quality and safety – such as ISO 13485 for quality management systems, IEC 62304 for software life-cycle processes and ISO 14971 for risk management – all recognized by Health Canada for medical device regulation (Health Canada 2025). Vendors must demonstrate systematic quality management, including design controls, software validation, cybersecurity safeguards and post-market surveillance. They are also required to report adverse events and maintain traceability of software versions deployed in clinical settings (Health Canada 2021).

While SaMD classification introduces additional compliance obligations, it also provides healthcare organizations with assurance that these tools meet recognized safety, quality and reliability standards. For boards and executives, this reduces procurement risk and helps filter out products that fall below acceptable thresholds.

Governance for Healthcare Leaders

Even with regulatory safeguards, healthcare organizations carry ultimate responsibility for how ambient AI scribes are deployed. Boards and executives must decide not only whether to adopt these tools, but also how to do so in ways that reflect organizational values and obligations to patients.

Healthcare organizations should establish AI scribe governance using a three-tiered model: strategic oversight (board-level accountability for policy, risk appetite and resource allocation), tactical management (operational committees including clinical, privacy, information technology [IT] and legal stakeholders meeting quarterly to review performance and incidents) and operational monitoring (frontline processes for daily error reporting, consent tracking and quality assurance).

Patient autonomy

Consent cannot be an afterthought. Patients must be able to see when scribes are in use, pause or revoke consent at any time and be assured that their choice will not affect care. Leaders should ensure that systems are in place to document and audit consent for every encounter. Protecting autonomy sustains trust at the heart of patient–provider relationships (Beauchamp and Childress 2019; WHO 2021).

Balancing benefits and burdens

Claims of efficiency and burnout reduction must be weighed against risks of new burdens. If clinicians spend more time correcting AI-generated errors or managing technical glitches, the net impact could be negative. Boards should require clear data from pilots and ongoing monitoring to confirm that technology delivers real benefits (Peterson Health Technology Institute 2025).

Equity and justice

AI scribes must work for all populations, not just patients who speak standard English. If performance varies by accent, language variety or background noise, organizations risk creating a two-tier system where documentation quality varies by patient demographics. Leaders must require vendors to provide performance metrics disaggregated by these factors and address gaps before scaling. Equity also means ensuring that access to technology is consistent across sites (Obermeyer et al. 2019).

Accountability and traceability

In the event of disputes or errors, organizations must be able to reconstruct what AI transcribed, what clinicians edited and when. Immutable audit logs and clear policies on clinician authorship are critical (European Union 2016; Information and Privacy Commissioner of Ontario 2025). Leaders should treat auditability as a minimum requirement.

Vendor management and interoperability

A critical governance decision is whether to standardize on a single approved AI scribe vendor or permit multiple solutions across the organization. A single vendor approach offers simplified quality monitoring, consistent performance metrics, streamlined training, stronger negotiating position and enhanced interprofessional documentation consistency – particularly important given that clinical documentation serves as a shared communication tool across disciplines. Multiple vendors offer the advantage of avoiding lock-in, accommodating specialty-specific optimization and providing departmental flexibility.

Regardless of vendor strategy, organizations must prioritize data portability and electronic health record (EHR) interoperability. Contracts should require that AI-generated documentation can be exported in standard formats if organizations switch vendors, seamless integration with existing EHR systems rather than parallel workflows, business associate agreements addressing data governance and security incident response and vendor obligations to maintain compatibility with organizational EHR upgrades. The strategic choice between single and multiple vendors should be made deliberately at the board and executive level, informed by organizational size, complexity and IT infrastructure maturity.

Continuous learning and oversight

Ambient AI is not a “set-and-forget” tool. Governance should include regular review of error reports, user feedback and vendor updates. Establishing AI oversight committees – or integrating into existing IT and clinical governance structures – can help ensure accountability. These bodies should include clinicians from multiple disciplines (physicians, nurses, nurse practitioners and allied health professionals), privacy officers, patients and security experts. By treating AI scribes as dynamic systems requiring active monitoring, organizations can adapt policies and practices as technology evolves (Health Canada 2019; WHO 2021).

Conclusion and Recommendations

Ambient AI scribes hold real promise for Canadian healthcare. Early evidence suggests that they can reduce documentation time by up to 20%, alleviate clinician burnout and strengthen patient–provider connections. For leaders managing strained health systems, these benefits are appealing. However, evidence also shows that outcomes are uneven. Without strong governance, organizations risk introducing new errors, undermining patient trust or widening inequities.

The leadership imperative is to view ambient AI scribes not as simple IT purchases, but as system-wide changes demanding ethical stewardship and careful oversight. Success depends on boards and executives asking the right questions, setting clear expectations and embedding safeguards from the start.

Key recommendations for leaders include treating clinicians as authors of record, with clear policies and training to avoid automation bias (Cohen et al. 2025); embedding transparent and revocable consent processes that give patients meaningful choice (College of Physicians and Surgeons of Ontario 2024; Minutti 2025); holding vendors accountable for privacy, security and equity, including explicit requirements for performance metrics across diverse patient populations (European Union 2016; Texas Medical Liability Trust 2025); supporting federal efforts to classify AI scribes as Class II SaMD (Health Canada 2019; NHS England 2025); establishing governance structures to provide continuous monitoring, error reporting and performance review (WHO 2021); piloting AI scribes systematically with specific clinical teams before full deployment; making deliberate organizational decisions about vendor strategies with mandatory requirements for data portability and EHR interoperability; and ensuring interprofessional representation in governance structures, recognizing that all clinical disciplines require tailored accountability frameworks aligned with their respective regulatory bodies.

For Canada's health system leaders, the choice is not whether ambient AI scribes will arrive – they are already here – but whether their adoption will be shaped by proactive governance or reactive crisis management. Leaders who act now to establish clear policies, demand vendor accountability and embed ethical safeguards will position their organizations to realize efficiency gains while strengthening rather than eroding public trust. Those who treat AI scribes as routine IT purchases risk discovering too late that they have introduced new liabilities, widened inequities or compromised patient–provider relationships.

The opportunity to shape this technology's trajectory is time-limited. Leadership that balances innovation with stewardship – that asks not only “Does this save time?” but also “Does this strengthen trust?” – will determine whether ambient AI scribes become catalysts for more humane care or simply another source of unintended consequences.

Artificial Intelligence-Assisted Statement

This article was prepared with the assistance of OpenAI's ChatGPT to improve clarity, coherence and formatting. The author reviewed and approved all content, ensuring that the intellectual and analytical contributions are entirely original.

Conflicts of Interest

The author has no conflicts of interest to declare.

Comments

Be the first to comment on this!